Form 4: Orchestra BioMed Holdings CEO David Hochman Acquires Additional Shares
SEC Form 4 Filing
David Hochman, CEO of Orchestra BioMed Holdings, recently purchased 2,500 shares of common stock at a price of $5.84 per share.
Summary
- On August 14, 2024, David Hochman, the CEO and Chairperson of Orchestra BioMed Holdings, Inc., acquired 2,500 shares of common stock.
- The purchase price was $5.84 per share.
- Following the transaction, Hochman directly owns 567,998 shares of common stock.
- He also indirectly owns 333,502 shares through the DPH 2008 Trust and 3,140 shares through the NSH 2008 Family Trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase indicates confidence, but it's a small transaction relative to overall holdings.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about their confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of the transaction where David Hochman acquired 2,500 shares of common stock. |
| 08/15/2024 | Date of signature by Andrew Taylor, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.